Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12319.165 | 0.8031 | 0.5725 | 0.9117 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12319.165 | 1.0868 | 1.1911 | 0.9117 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12319.165 | 1.0288 | 1.0632 | 0.9117 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12319.165 | 0.7785 | 0.5197 | 0.9117 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12319.165 | 1.0244 | 1.0535 | 0.9117 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12319.165 | 0.4924 | -0.0804 | 0.9117 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12319.165 | 0.0143 | -0.9811 | 0.9117 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12319.165 | 0.0055 | -0.9934 | 0.9117 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12580.165 | 1.1624 | 1.1359 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12580.165 | 0.9163 | 0.9250 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12580.165 | 0.6872 | 0.6975 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12580.165 | 0.3459 | 0.2576 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12580.165 | 0.3384 | 0.2456 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12580.165 | 0.2975 | 0.1775 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12580.165 | 0.1090 | -0.2408 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12580.165 | 0.0311 | -0.5611 | 2.2883 | |
| MB 157 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12580.165 | 0.0095 | -0.7389 | 2.2883 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11056.158 | 1.0208 | 1.0151 | 2.7355 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11056.158 | 1.0159 | 1.0116 | 2.7355 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11056.158 | 1.0066 | 1.0048 | 2.7355 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11056.158 | 0.6671 | 0.7249 | 2.7355 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11056.158 | 0.2183 | 0.1465 | 2.7355 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11056.158 | 0.1946 | 0.0994 | 2.7355 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11056.158 | 0.1512 | 0.0025 | 2.7355 | |
| MCF 10A | NM | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11056.158 | 0.0076 | -0.6647 | 2.7355 |